Silver Book Fact

30 drugs are currently in development for osteoporosis.

PhRMA. 2008 Report: Medicines in Development for Older Americans; November 2008

Reference

Title
2008 Report: Medicines in Development for Older Americans
Publication Date
November 2008
Authors
PhRMA

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • Raloxifene, a selective estrogen receptor modulator (SERM), has been shown to decrease vertebral fractures by up to 50% after 3 years.  
  • Risedronate, a bisphosphonate, has been shown to increase vertebral bone mineral density (BMD) by around 5% and hip BMD by 2% to 3% in postmenopausal women with osteoporosis.  
  • Treatment with bisphosphonates are highly cost-effective in women over the age of 70 with osteoporosis and a previous fracture.  
  • Randomized controlled trials give evidence that pharmacologic therapy can reduce risk of fractures by 40 to 50%.  
  • A meta-analysis of clinical trials found that Vitamin D supplements reduced the risk of vertebral fractures by around 37%.